Created in Toulouse in 2005, ABIONYX Pharma is a new generation biotech company listed on the Euronext Paris stock exchange (FR0012616852 – ABNX – PEA PME eligible) dedicated to the discovery and development of innovative biotherapies.
Its portfolio of biomedicines is based on one of the most abundant proteins in human blood, ApoA-I. The company designs and industrially produces a mimetic HDL based on the only recombinant apoA-I in the world for which it holds all the patents, which makes it possible to briefly treat severe diseases in certain renal indications and Sepsis or to deliver targeted medications. active ingredients for ophthalmological diseases.
Concerning Sepsis, 3th a cause of death affecting more than 14 million people per year worldwide, there is currently no approved treatment. Given the aging of the population and the possible emergence of new pathogens due to global warming, the number of patients could double by 2050. Its Phase 2a clinical study for CER-001 (called RACERS) in the Sepsis, carried out in partnership with the University of Bari (Italy), produced major positive clinical results. The company is currently preparing for a Phase IIb/III which will begin soon in the US and Europe.
Concerning the orphan disease LCAT (lecithin-cholesterol-acyl-transferase-LCAT deficiency), a rare genetic disorder that affects the kidneys and eyes, the company continues to receive new requests for Compassionate Access Authorization from several hospitals in the world and plans a Marketing Authorization request soon.
Finally, in ophthalmology, the preclinical studies carried out by its subsidiary dedicated to contract research IRIS Pharma have proven very positive. In March 2024, the company received innovation aid of nearly 1 million euros from Bpifrance to continue its programs in the field.
The company has 60 employees.